News | March 29, 2025
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Experts urge early detection & better access to care
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
There are 38.4 million people with diabetes in the United States
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Offers affordable, high-quality solutions for diabetes care
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Subscribe To Our Newsletter & Stay Updated
